Q4 2025 EPS Estimates for Biogen Inc. (NASDAQ:BIIB) Cut by Analyst

Biogen Inc. (NASDAQ:BIIB - Free Report) - Research analysts at Zacks Research reduced their Q4 2025 earnings per share (EPS) estimates for shares of Biogen in a report released on Tuesday, April 2nd. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $4.58 for the quarter, down from their prior estimate of $4.72. The consensus estimate for Biogen's current full-year earnings is $15.48 per share.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $2.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.18 by ($0.23). Biogen had a net margin of 11.81% and a return on equity of 14.91%. The company had revenue of $2.39 billion during the quarter, compared to analysts' expectations of $2.47 billion. During the same quarter in the prior year, the business posted $4.05 earnings per share.

A number of other analysts have also recently weighed in on BIIB. Cantor Fitzgerald reissued an "overweight" rating and issued a $311.00 price objective on shares of Biogen in a research report on Tuesday, February 20th. Piper Sandler dropped their price target on shares of Biogen from $350.00 to $325.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 14th. Canaccord Genuity Group decreased their price target on shares of Biogen from $310.00 to $305.00 and set a "buy" rating on the stock in a research note on Tuesday, February 20th. Wedbush raised their price target on shares of Biogen from $239.00 to $245.00 and gave the company a "neutral" rating in a research note on Monday, February 12th. Finally, Barclays decreased their price target on shares of Biogen from $230.00 to $215.00 and set an "equal weight" rating on the stock in a research note on Thursday. Nine equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $302.52.

Biogen Stock Down 0.5 %

Shares of NASDAQ:BIIB traded down $1.08 on Thursday, reaching $205.30. The company had a trading volume of 776,100 shares, compared to its average volume of 1,169,792. The company has a current ratio of 2.00, a quick ratio of 1.26 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $29.84 billion, a PE ratio of 26.02, a PEG ratio of 1.73 and a beta of -0.02. Biogen has a 52-week low of $205.22 and a 52-week high of $319.76. The firm's 50 day simple moving average is $226.03 and its 200-day simple moving average is $240.51.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 419 shares of Biogen stock in a transaction on Monday, February 12th. The shares were sold at an average price of $239.45, for a total transaction of $100,329.55. Following the completion of the sale, the insider now directly owns 4,516 shares of the company's stock, valued at approximately $1,081,356.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Priya Singhal sold 419 shares of Biogen stock in a transaction on Monday, February 12th. The shares were sold at an average price of $239.45, for a total transaction of $100,329.55. Following the completion of the sale, the insider now directly owns 4,516 shares of the company's stock, valued at approximately $1,081,356.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Eric K. Rowinsky acquired 455 shares of the firm's stock in a transaction dated Thursday, February 15th. The shares were purchased at an average cost of $222.54 per share, with a total value of $101,255.70. Following the completion of the transaction, the director now owns 20,629 shares in the company, valued at approximately $4,590,777.66. The disclosure for this purchase can be found here. Insiders sold 882 shares of company stock valued at $202,030 in the last 90 days. Company insiders own 0.60% of the company's stock.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Primecap Management Co. CA increased its stake in Biogen by 1.6% in the fourth quarter. Primecap Management Co. CA now owns 16,264,481 shares of the biotechnology company's stock valued at $4,208,760,000 after purchasing an additional 251,915 shares during the period. Vanguard Group Inc. increased its stake in Biogen by 18.2% in the fourth quarter. Vanguard Group Inc. now owns 14,407,330 shares of the biotechnology company's stock valued at $3,728,185,000 after purchasing an additional 2,218,744 shares during the period. State Street Corp increased its stake in Biogen by 2.8% in the first quarter. State Street Corp now owns 7,208,906 shares of the biotechnology company's stock valued at $1,518,196,000 after purchasing an additional 197,400 shares during the period. Wellington Management Group LLP increased its stake in Biogen by 0.5% in the third quarter. Wellington Management Group LLP now owns 5,374,310 shares of the biotechnology company's stock valued at $1,381,251,000 after purchasing an additional 27,951 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Biogen by 49.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,088,356 shares of the biotechnology company's stock valued at $580,627,000 after purchasing an additional 691,843 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.